English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
NEWS
Press Release
Media Report
Year:
Select
2024
2023
2022
2021
2020
2019
2018
2016
Press Release
16
September 2024
Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors.
16
August 2024
Alphamab Oncology Reports 2024 Interim Results and Business Highlights
2024 Interim Results and Business Highlights
12
August 2024
Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
Onsite Poster display date: Saturday, 14 September 2024
06
June 2024
Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products
Alphamab and ArriVent will collaborate to use Alphamab's proprietary linker-payload (Alphatecan) and glycan-conjugation platforms to discover and develop novel ADCs
03
June 2024
Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting
JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dos...
22
May 2024
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016
an open-label, multi-center, first-in-human (FIH) phase I clinical trial of JSKN016
06
May 2024
Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
Session Date and Time: 6/1/2024 9:00 AM-12:00 PM CDT
10
April 2024
Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR
JSKN003 demonstrated encouraging preliminary antitumor activity in heavily pretreated patients with advanced/metastatic solid tumors
29
March 2024
Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights
Alphamab Oncology continued to focus on addressing clinical needs and adhere to differentiated innovation
26
March 2024
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033
the nature of subcutaneous injectable will lead to improved safety and convenience
1
2
3
4
PREV
1/18
NEXT
